Top Markets
Coin of the day
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
Rang in aandelen #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Aandeelprijs
$0.00047446
Marktkapitalisatie
$82.80
Verandering (1 dag)
0.00%
Verandering (1 jaar)
-98.16%
Land
FR
Handel Neovacs S.A. (ALNEV)

Categorie

EPS voor Neovacs S.A. (ALNEV)
EPS per December 2024 TTM: $-34.55K
Volgens de laatste financiële rapporten en de aandelenkoers van Neovacs S.A. is de huidige EPS van het bedrijf (TTM) $-34.55K. Eind 2023 had het bedrijf een EPS van $-275.26K, een stijging ten opzichte van de EPS van 2022 die $-1.26 bedroeg.
EPS-geschiedenis van Neovacs S.A. van 2007 tot 2026
EPS aan het einde van elk jaar
Jaar EPS Wijzigen
2026 (TTM) $-34.55K 17,504.17%
2024 $-196.26 -99.93%
2023 $-275.26K 21,820,011.06%
2022 $-1.26 -100.00%
2021 $-5.367T -93.96%
2020 $-88.856T -79.32%
2019 $-429.767T -54.85%
2018 $-951.868T -52.78%
2017 $-2.02Qa -24.26%
2016 $-2.66Qa 115.81%
2015 $-1.23Qa -59.95%
2014 $-3.08Qa -17.40%
2013 $-3.73Qa -18.52%
2012 $-4.58Qa -9.86%
2011 $-5.08Qa -27.43%
2010 $-6.99Qa 21.97%
2009 $-5.73Qa 53.05%
2008 $-3.75Qa -7.11%
2007 $-4.03Qa 0.00%
EPS van vergelijkbare bedrijven of concurrenten
Bedrijf EPS EPS-verschil Land
$3.62 -100.01%
DK
$15.47 -100.04%
US
$43.12 -100.12%
US
$9.62 -100.03%
BE
$38.32 -100.11%
NL